Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
Positive association mainly driven by incidence of papillary thyroid cancer.
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
Increasing trends in global thyroid cancer burden were observed in a cross-sectional study using data from 195 countries in 21 regions.
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Significant slowing found in rate of increase from 2009 to 2014, followed by stable rate since 2014.